Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00085943 · ClinicalTrials.gov registry record · Phase 3
KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 866
- Enrollment target
NCT00085943: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT00085943 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 866 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00085943, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 866 participants
- Enrollment target
Study Summary
This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 copies/mL of blood. In addition we will study the safety and tolerability of these compounds over the 48 week study period in patients naive to anti-HIV therapy.
Interventions
- DRUG Ritonavir
- DRUG LEXIVA (GW433908)
- DRUG KALETRA
- DRUG EPIVIR
- DRUG Ziagen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 866 participants |
| Start Date | 2004-05 |
| Phase | Phase 3 |
What the finished NCT00085943 record still lists
NCT00085943 is an interventional study that assigns participants to a tested intervention. The registered 866 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 5 interventions - of which Ritonavir is the first listed.
NCT00085943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00085943 about?
NCT00085943 is a clinical study titled "KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks". This study will compare the ability of fosamprenavir 700 mg with ritonavir 100 mg twice a day or lopinavir 400 mg with ritonavir 100 mg twice a day both combined with a fixed dose combination tablet of abacavir 600 mg and lamivudine 300 mg once a day to suppress virus levels of HIV to less than 400 ...
What is the current status of trial NCT00085943?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 866 participants. The study started on 2004-05.
What interventions are being tested in trial NCT00085943?
The interventions under investigation include: Ritonavir (DRUG), LEXIVA (GW433908) (DRUG), KALETRA (DRUG), EPIVIR (DRUG), Ziagen (DRUG).
Who is sponsoring clinical trial NCT00085943?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00085943's enrollment target sits among peer trials
866 376th of 2000 higher than 1,624 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04933552 · 867 participants
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
- NCT05369052 · 865 participants · Phase 3
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia